Symbols / WVE Stock $7.07 -1.53% Wave Life Sciences Ltd.

Healthcare • Biotechnology • Singapore • NGM
WVE (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Paul B. Bolno M.B.A., M.D.
Exch · Country NGM · Singapore
Market Cap 1.36B
Enterprise Value 852.41M
Income -183.59M
Sales 71.80M
FCF (ttm) -125.72M
Book/sh 2.76
Cash/sh 2.83
Employees 317
Insider 10d —
IPO Nov 11, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.38
PEG —
P/S 18.95
P/B 2.56
P/C —
EV/EBITDA -4.41
EV/Sales 11.87
Quick Ratio 10.93
Current Ratio 11.26
Debt/Eq 3.07
LT Debt/Eq —
EPS (ttm) -1.05
EPS next Y -1.11
EPS Growth —
Revenue Growth 3.17%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-29
Earnings (prior) 2026-04-28
ROA -28.23%
ROE -53.10%
ROIC —
Gross Margin -164.07%
Oper. Margin -81.83%
Profit Margin -255.70%
Shs Outstand 192.40M
Shs Float 90.47M
Insider Own 15.92%
Instit Own 92.37%
Short Float 8.85%
Short Ratio 2.06
Short Interest 13.35M
52W High 21.73
vs 52W High -67.46%
52W Low 5.02
vs 52W Low 40.84%
Beta -1.32
Impl. Vol. 79.49%
Rel Volume 0.67
Avg Volume 4.41M
Volume 2.96M
Target (mean) $22.19
Tgt Median $18.50
Tgt Low $12.00
Tgt High $43.00
# Analysts 16
Recom Strong_buy
Prev Close $7.18
Price $7.07
Change -1.53%
About

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$22.19
Mean price target
2. Current target
$7.07
Latest analyst target
3. DCF / Fair value
$-11.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.07
Low
$12.00
High
$43.00
Mean
$22.19

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-04 main Citigroup Buy → Buy $24
2026-04-30 main Canaccord Genuity Buy → Buy $43
2026-04-29 main Truist Securities Buy → Buy $15
2026-04-14 main HC Wainwright & Co. Buy → Buy $18
2026-03-27 main B of A Securities Buy → Buy $21
2026-03-27 main Wells Fargo Overweight → Overweight $13
2026-03-25 main Mizuho Outperform → Outperform $27
2026-03-10 main Canaccord Genuity Buy → Buy $52
2026-03-06 main Wedbush Outperform → Outperform $35
2026-03-02 reit HC Wainwright & Co. Buy → Buy $30
2026-02-12 main Wells Fargo Overweight → Overweight $27
2026-02-05 main Cantor Fitzgerald Overweight → Overweight $41
2026-02-03 main Canaccord Genuity Buy → Buy $43
2025-12-19 main HC Wainwright & Co. Buy → Buy $30
2025-12-16 main Oppenheimer Outperform → Outperform $32
2025-12-15 main Truist Securities Buy → Buy $50
2025-12-12 main B. Riley Securities Buy → Buy $37
2025-12-12 main Wedbush Outperform → Outperform $33
2025-12-09 main Citigroup Buy → Buy $30
2025-12-09 main Canaccord Genuity Buy → Buy $40
News
RSS: Latest WVE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-30 RA CAPITAL MANAGEMENT, L.P. Beneficial Owner of more than 10% of a Class of Security — 8,772,496 $6.06 $54,624,378
2026-03-23 TAKANASHI KEN Director — 3,901,348 — —
2026-02-26 FRANCIS CHRISTOPHER JOHN Officer — 33,194 $15.00 $499,593
2026-02-26 FRANCIS CHRISTOPHER JOHN Officer — 33,194 $3.87 $141,920
2026-02-09 MORAN KYLE Chief Financial Officer — 3,588 $13.45 $48,259
2026-02-09 BOLNO PAUL B. M.D. Chief Executive Officer — 10,480 $13.45 $140,956
2026-02-09 VARGEESE CHANDRA Officer — 3,228 $13.45 $43,417
2026-02-09 FRANCIS CHRISTOPHER JOHN Officer — 1,883 $13.45 $25,326
2026-02-05 MORAN KYLE Chief Financial Officer — 45,625 $0.00 $0
2026-02-05 BOLNO PAUL B. M.D. Chief Executive Officer — 165,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
42.73
-60.55%
108.30
-4.42%
113.31
+3005.10%
3.65
Operating Revenue
42.73
-60.55%
108.30
-4.42%
113.31
+3005.10%
3.65
Operating Expense
258.11
+18.02%
218.71
+20.63%
181.30
+8.98%
166.37
Research And Development
182.78
+14.46%
159.68
+22.82%
130.01
+12.22%
115.86
Selling General And Administration
75.33
+27.63%
59.02
+15.07%
51.29
+1.54%
50.51
General And Administrative Expense
75.33
+27.63%
59.02
+15.07%
51.29
+1.54%
50.51
Other Gand A
75.33
+27.63%
59.02
+15.07%
51.29
+1.54%
50.51
Total Expenses
258.11
+18.02%
218.71
+20.63%
181.30
+8.98%
166.37
Operating Income
-215.38
-95.09%
-110.40
-62.37%
-68.00
+58.21%
-162.72
Total Operating Income As Reported
-215.38
-95.09%
-110.40
-62.37%
-68.00
+58.21%
-162.72
EBITDA
-206.53
-103.00%
-101.74
-73.06%
-58.79
+61.48%
-152.61
Normalized EBITDA
-217.01
-93.93%
-111.90
-67.73%
-66.72
+56.73%
-154.18
Reconciled Depreciation
8.85
+2.18%
8.66
-5.90%
9.21
-8.98%
10.11
EBIT
-215.38
-95.09%
-110.40
-62.37%
-68.00
+58.21%
-162.72
Total Unusual Items
10.48
+3.10%
10.16
+28.19%
7.93
+404.65%
1.57
Total Unusual Items Excluding Goodwill
10.48
+3.10%
10.16
+28.19%
7.93
+404.65%
1.57
Net Income
-204.38
-110.68%
-97.01
-68.67%
-57.51
+64.46%
-161.82
Pretax Income
-204.38
-110.68%
-97.01
-66.71%
-58.19
+63.89%
-161.14
Other Income Expense
11.01
-17.84%
13.39
+36.60%
9.81
+521.42%
1.58
Other Non Operating Income Expenses
0.53
-83.69%
3.23
+72.10%
1.88
+26728.57%
0.01
Gain On Sale Of Security
10.48
+3.10%
10.16
+28.19%
7.93
+404.65%
1.57
Tax Provision
0.00
0.00
+100.00%
-0.68
-199.41%
0.68
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
-93.16%
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
0.09
-65.46%
0.27
Net Income Including Noncontrolling Interests
-204.38
-110.68%
-97.01
-68.67%
-57.51
+64.46%
-161.82
Net Income From Continuing Operation Net Minority Interest
-204.38
-110.68%
-97.01
-68.67%
-57.51
+64.46%
-161.82
Net Income From Continuing And Discontinued Operation
-204.38
-110.68%
-97.01
-68.67%
-57.51
+64.46%
-161.82
Net Income Continuous Operations
-204.38
-110.68%
-97.01
-68.67%
-57.51
+64.46%
-161.82
Normalized Income
-214.86
-100.48%
-107.17
-64.00%
-65.35
+59.94%
-163.13
Net Income Common Stockholders
-204.38
-110.68%
-97.01
-68.67%
-57.51
+64.46%
-161.82
Diluted EPS
-1.21
-72.86%
-0.70
-29.63%
-0.54
+73.66%
-2.05
Basic EPS
-1.21
-72.86%
-0.70
-29.63%
-0.54
+73.66%
-2.05
Basic Average Shares
168.65
+21.96%
138.28
+30.33%
106.10
+34.55%
78.86
Diluted Average Shares
168.65
+21.96%
138.28
+30.33%
106.10
+34.55%
78.86
Diluted NI Availto Com Stockholders
-204.38
-110.68%
-97.01
-68.67%
-57.51
+64.46%
-161.82
Line Item Trend 2023-12-31
Total Assets
274.95
Current Assets
235.37
Cash Cash Equivalents And Short Term Investments
200.35
Cash And Cash Equivalents
200.35
Receivables
21.09
Accounts Receivable
21.09
Prepaid Assets
9.91
Other Current Assets
4.02
Total Non Current Assets
39.58
Net PPE
35.72
Gross PPE
78.43
Accumulated Depreciation
-42.71
Properties
0.00
Machinery Furniture Equipment
26.97
Construction In Progress
0.29
Other Properties
22.64
Leases
28.52
Other Non Current Assets
3.85
Total Liabilities Net Minority Interest
235.32
Current Liabilities
186.44
Payables And Accrued Expenses
15.60
Payables
12.84
Accounts Payable
12.84
Current Accrued Expenses
2.76
Pensionand Other Post Retirement Benefit Plans Current
14.06
Current Debt And Capital Lease Obligation
6.71
Current Capital Lease Obligation
6.71
Current Deferred Liabilities
150.06
Current Deferred Revenue
150.06
Total Non Current Liabilities Net Minority Interest
48.88
Long Term Debt And Capital Lease Obligation
25.40
Long Term Capital Lease Obligation
25.40
Non Current Deferred Liabilities
15.60
Non Current Deferred Revenue
15.60
Other Non Current Liabilities
—
Preferred Securities Outside Stock Equity
7.87
Stockholders Equity
39.63
Common Stock Equity
39.63
Capital Stock
935.37
Common Stock
935.37
Share Issued
119.16
Ordinary Shares Number
119.16
Treasury Shares Number
0.00
Additional Paid In Capital
129.24
Retained Earnings
-1,024.85
Gains Losses Not Affecting Retained Earnings
-0.12
Other Equity Adjustments
-0.12
Total Equity Gross Minority Interest
39.63
Total Capitalization
39.63
Working Capital
48.93
Invested Capital
39.63
Total Debt
32.12
Capital Lease Obligations
32.12
Net Tangible Assets
39.63
Tangible Book Value
39.63
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-187.49
-24.15%
-151.03
-677.24%
-19.43
+84.79%
-127.78
Cash Flow From Continuing Operating Activities
-187.49
-24.15%
-151.03
-677.24%
-19.43
+84.79%
-127.78
Net Income From Continuing Operations
-204.38
-110.68%
-97.01
-68.67%
-57.51
+64.46%
-161.82
Depreciation Amortization Depletion
8.85
+2.18%
8.66
-5.90%
9.21
-8.98%
10.11
Depreciation
8.85
+2.18%
8.66
-5.90%
9.21
-8.98%
10.11
Depreciation And Amortization
8.85
+2.18%
8.66
-5.90%
9.21
-8.98%
10.11
Stock Based Compensation
24.97
+90.04%
13.14
+34.16%
9.79
-43.03%
17.19
Operating Gains Losses
—
—
—
0.01
Gain Loss On Sale Of PPE
—
0.00
0.00
-100.00%
0.01
Change In Working Capital
-16.94
+77.66%
-75.82
-497.37%
19.08
+183.86%
6.72
Change In Receivables
0.15
-99.26%
19.66
+193.26%
-21.09
0.00
Changes In Account Receivables
0.15
-99.26%
19.66
+193.26%
-21.09
0.00
Change In Prepaid Assets
1.15
+212.23%
0.37
+118.59%
-1.98
-46.88%
-1.35
Change In Payables And Accrued Expense
4.92
-35.86%
7.67
+271.10%
-4.49
-137.25%
12.04
Change In Accrued Expense
5.48
+28.92%
4.25
+687.43%
-0.72
-126.90%
2.69
Change In Payable
-0.56
-116.40%
3.42
+190.96%
-3.76
-140.23%
9.35
Change In Account Payable
-0.56
-116.40%
3.42
+190.96%
-3.76
-140.23%
9.35
Change In Other Working Capital
-19.83
+78.81%
-93.59
-272.27%
54.33
+1774.21%
-3.25
Change In Other Current Assets
4.31
+233.77%
-3.23
-60.45%
-2.01
-159.22%
3.39
Change In Other Current Liabilities
-7.64
-13.76%
-6.71
-18.08%
-5.69
-38.08%
-4.12
Investing Cash Flow
-0.72
+23.45%
-0.94
+15.87%
-1.11
+11.16%
-1.25
Cash Flow From Continuing Investing Activities
-0.72
+23.45%
-0.94
+15.87%
-1.11
+11.16%
-1.25
Net PPE Purchase And Sale
-0.72
+23.45%
-0.94
+15.87%
-1.11
+11.16%
-1.25
Purchase Of PPE
-0.72
+23.45%
-0.94
+15.87%
-1.11
+18.07%
-1.36
Sale Of PPE
—
0.00
0.00
-100.00%
0.11
Capital Expenditure
-0.72
+23.45%
-0.94
+15.87%
-1.11
+18.07%
-1.36
Net Investment Purchase And Sale
—
0.00
0.00
0.00
Purchase Of Investment
—
0.00
0.00
+100.00%
-75.04
Sale Of Investment
—
0.00
0.00
-100.00%
75.04
Financing Cash Flow
488.24
+92.30%
253.89
+91.57%
132.53
+97.26%
67.19
Cash Flow From Continuing Financing Activities
488.24
+92.30%
253.89
+91.57%
132.53
+97.26%
67.19
Net Common Stock Issuance
472.49
+100.06%
236.18
+79.91%
131.28
+150.89%
52.33
Proceeds From Stock Option Exercised
15.75
-11.09%
17.71
+1309.23%
1.26
-91.54%
14.86
Changes In Cash
300.02
+194.35%
101.93
-8.98%
111.99
+281.07%
-61.85
Effect Of Exchange Rate Changes
0.01
+108.70%
-0.14
-45.26%
-0.10
+54.76%
-0.21
Beginning Cash Position
305.84
+49.88%
204.05
+121.42%
92.16
-40.24%
154.22
End Cash Position
605.87
+98.10%
305.84
+49.88%
204.05
+121.42%
92.16
Free Cash Flow
-188.21
-23.85%
-151.96
-639.63%
-20.55
+84.09%
-129.14
Common Stock Issuance
472.49
+100.06%
236.18
+79.91%
131.28
+150.89%
52.33
Issuance Of Capital Stock
472.49
+100.06%
236.18
+79.91%
131.28
+150.89%
52.33
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category